The vesicles in question are exosomes, nanoscale membrane-bound sacs that cells release as biological mail. Rather than injecting whole stem cells — an approach that carries risks of uncontrolled growth, immune reactions and poor targeting — clinicians and researchers have increasingly turned to the exosomes those cells secrete. These vesicles are low in immunogenicity, biologically compatible, and small enough to slip into tissues and deliver their cargo of nucleic acids, proteins and lipids directly into recipient cells. The new study focused on exosomes harvested from adipose mesenchymal stem cells, or AMSCs, which have already shown promise in preclinical work for improving blood flow and reducing inflammation in renovascular disease.

To understand why the kidney responds so well to this treatment, one has to appreciate the peculiar metabolic predicament of tubular epithelial cells, the workhorses of the nephron. These cells normally burn fatty acids in their mitochondria, a process called fatty acid oxidation, to generate the enormous amounts of energy the kidney requires for filtering blood. But when oxygen supply dips — as it does in fibrotic kidneys — fatty acid oxidation is suppressed for far longer than the hypoxic insult itself, and the cells cannot compensate by burning carbohydrates instead. Surviving tubular cells therefore undergo a phenotypic switch: they rearrange their cytoskeleton, produce more extracellular matrix proteins, and ramp up glycolysis, the less efficient sugar-burning pathway. This metabolic reprogramming is now recognized as a hallmark of chronic kidney disease progression.

The Chinese team, led by Chi Zhang of Xuzhou Medical University and colleagues, set out to determine whether AMSC-derived exosomes could interrupt this metabolic derailment. They first isolated and purified the exosomes by ultracentrifugation, confirming their characteristic 50–200 nanometer size and bilayer membrane structure by transmission electron microscopy and nanoparticle tracking analysis. Western blotting verified the presence of canonical exosomal markers — CD9, CD81 and Tsg101 — while the absence of the negative marker Calnexin indicated minimal contamination from intracellular organelles. With the vesicles authenticated, the researchers moved to a well-established mouse model of renal fibrosis: unilateral ureteral obstruction, or UUO, in which the left ureter is surgically ligated, causing urine to back up and progressive scarring to develop in the affected kidney.

Seven days after UUO surgery — a time point chosen to capture early fibrogenic events before extensive tissue destruction obscures the underlying mechanisms — the researchers injected AMSC-derived exosomes intravenously. The results were dramatic. Western blotting of kidney tissue showed that levels of HIF-1α, the master hypoxia marker, and α-SMA, a fibrosis marker, were markedly elevated in untreated UUO mice but substantially reduced in the exosome-treated group. Histological staining with hematoxylin and eosin and Masson’s trichrome revealed that exosome administration lessened tubular dilation, eased tubular epithelial cell damage, and significantly improved fibrosis, with minimal inflammatory cell infiltration. Immunohistochemistry for α-SMA confirmed that the vesicles efficiently suppressed myofibroblast activation, the cellular engine of collagen deposition.

But the researchers wanted to know precisely which molecule inside the exosomes was doing the work. Using miRNA sequencing, they identified the five most abundant microRNAs in AMSC-derived exosomes: miR-26a-5p, miR-150-5p, miR-1301-3p, miR-193a-3p and miR-33a-3p, together accounting for nearly 48 percent of the total miRNA population. MicroRNAs are short non-coding RNA strands that bind to complementary sequences in messenger RNAs, tagging them for degradation or blocking their translation into protein. Among the five candidates, miR-26a-5p stood out for its prevalence and its prior association with anti-fibrotic effects. Bioinformatic screening across the TargetScan and miRWalk databases pointed to a single compelling target: Pfkfb3, an enzyme that encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, a critical regulator of glycolysis.

To validate that miR-26a-5p genuinely targets Pfkfb3, the team performed a dual-luciferase reporter assay, co-transfecting 293T cells with either wild-type or mutant Pfkfb3 3′UTR constructs alongside miR-26a-5p mimics or inhibitors. The results confirmed a conserved binding site in the Pfkfb3 3′UTR. The researchers then generated exosomes from AMSCs transfected with a miR-26a-5p inhibitor and injected these depleted vesicles into UUO mice. The outcome was telling: when miR-26a-5p was knocked down, the exosomes lost their ability to suppress Pfkfb3, and the protective effects on kidney damage and fibrosis were markedly weakened. Histology showed exacerbated tubulointerstitial injury in mice receiving the miR-26a-5p-depleted exosomes, accompanied by upregulated Pfkfb3 — establishing miR-26a-5p as the functional mediator of the exosomes’ anti-fibrotic action.

With Pfkfb3 confirmed as the target, the researchers traced the downstream metabolic consequences. In both hypoxic HK-2 human proximal tubular cells and UUO mouse kidneys, AMSC-derived exosomes downregulated the expression of key glycolytic checkpoint enzymes — hexokinase 2 (HK2), phosphofructokinase muscle type (PFKM) and lactate dehydrogenase A (LDHA) — at both mRNA and protein levels. Lactate concentration, a direct readout of glycolytic flux, was significantly reduced in exosome-treated cells and tissues, while it rose further in the miR-26a-5p-depleted group. These findings indicate that the exosomes suppress the glycolytic reprogramming that fibrotic kidneys undergo, rather than merely damping inflammation or collagen production.

The most surprising twist came when the team probed the connection between Pfkfb3 and ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation. Transmission electron microscopy of kidney tissue revealed severe mitochondrial destruction — damaged cristae, reduced mitochondrial number, and morphological collapse — in untreated UUO mice and in mice receiving miR-26a-5p-depleted exosomes. AMSC-derived exosomes protected mitochondria from this damage. JC-1 staining showed that mitochondrial membrane potential, a key indicator of mitochondrial health, was preserved by exosome treatment but collapsed in the depleted group. MitoSOX analysis confirmed that mitochondrial superoxide production, a major source of reactive oxygen species, was elevated in the hypoxic and miR-26a-5p-depleted groups and reduced by exosome administration.

At the molecular level, the ferroptosis regulators told a coherent story. GPX4, the glutathione peroxidase enzyme that protects cells against lipid peroxidation and ferroptotic death, was significantly downregulated in untreated UUO and hypoxic groups, while ACSL4, an acyl-CoA synthetase involved in ferroptosis execution, was upregulated. Knocking down miR-26a-5p exacerbated both changes. Critically, the researchers performed a rescue experiment using PFK15, a specific Pfkfb3 inhibitor, in cells where miR-26a-5p had been knocked down. PFK15 reversed the damage: it reduced Pfkfb3 and HK2 expression, restored GPX4 levels, and suppressed ACSL4. This causal chain — miR-26a-5p suppresses Pfkfb3, which in turn dampens both glycolysis and ferroptosis — establishes Pfkfb3 as a functional bridge between metabolic reprogramming and cell death in fibrotic kidneys.

The implications reach beyond the laboratory bench. Renal fibrosis is the final common pathway of virtually all chronic kidney diseases, regardless of whether the initial insult is diabetes, hypertension, glomerulonephritis or genetic disease. Current anti-fibrotic therapies show limited efficacy in halting or reversing this progression, and the field has long sought strategies that target the underlying cellular mechanisms rather than downstream symptoms. The new work suggests that exosome-based delivery of miR-26a-5p could offer a safer, more targeted alternative to whole-cell stem cell therapy, exploiting the vesicles’ natural ability to home to injured tissues and deliver their microRNA cargo directly into tubular epithelial cells.

Several questions remain before this approach can move toward clinical testing. The study used a seven-day UUO model, which captures early fibrogenic events but does not address whether the treatment works in advanced fibrosis with extensive tissue destruction. The researchers focused on a single microRNA, but exosomes carry hundreds of bioactive molecules whose combined effects may differ from the isolated action of miR-26a-5p. Dosing, biodistribution, long-term safety and the behavior of exosomes in human kidneys all require further investigation. Still, the mechanistic clarity of the findings — a specific microRNA, a specific target enzyme, and a specific causal chain linking metabolism to cell death — gives the field a concrete molecular handle on a disease process that has resisted intervention for decades.

What makes this study particularly compelling is the way it reframes renal fibrosis as a metabolic disease. Rather than viewing the scarring process purely as an inflammatory or collagen-deposition problem, the work positions the glycolytic switch and the ferroptotic death of tubular epithelial cells as central, mechanistically linked drivers of fibrosis progression. By delivering a single microRNA that suppresses Pfkfb3, AMSC-derived exosomes simultaneously cool the glycolytic fire and shield mitochondria from ferroptotic collapse. This integrated regulatory mechanism — the miR-26a-5p/Pfkfb3 axis — offers a template for how cell-based therapies might be distilled into their most potent molecular components, and it hints that the next generation of anti-fibrotic treatments may look less like drugs and more like carefully engineered biological mail.

Subject of Research: Adipose Mesenchymal Stem Cells Secreted Exosomal miR‐26a‐5p Ameliorate Renal Fibrosis via Inhibiting Glycolysis and Ferroptosis in Renal Interstitial Fibrosis

Article Title: Adipose Mesenchymal Stem Cells Secreted Exosomal miR‐26a‐5p Ameliorate Renal Fibrosis via Inhibiting Glycolysis and Ferroptosis in Renal Interstitial Fibrosis

Article References: Zhang, C., Ge, R., Liu, M., Huang, J., Cai, J., Sun, T., Ge, S., Li, Q., & Zhang, Y. (2026). Adipose Mesenchymal Stem Cells Secreted Exosomal miR ‐26a‐5p Ameliorate Renal Fibrosis via Inhibiting Glycolysis and Ferroptosis in Renal Interstitial Fibrosis. Journal of Cellular and Molecular Medicine, 30(20), Article e71369. https://doi.org/10.1111/jcmm.71369

Image Credits: AI Generated

DOI: 10.1111/jcmm.71369

Keywords: Adipose, Mesenchymal, Stem, Cells, Secreted, Exosomal, Ameliorate, Renal, Fibrosis, Inhibiting, Glycolysis, Ferroptosis